Company Striving Towards Near-Term Profitability Following Go-to-Market Approach Revamp and Cost Reduction Initiatives

BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC (antibody drug conjugate) platform technology and Akari’s PAS-nomacopan Geographic Atrophy (GA) program. Peak’s ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari’s PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA.  

FORM 8.3

FORM 8.3

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed

TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (TSXV: NOW) (OTCQB: NOWVF) (“NOW” or the “Company”), is pleased to announce that NOW and Mostafa Hashem, NOW’s EVP Product & Technology have agreed to amend the outstanding earnout obligations governing NOW’s acquisition of Smartlytics Consultancy Limited (“Smartlytics”). In connection with the amendment, the incentives that Mr. Hashem would have received as a former owner of Smartlytics have been adjusted with the objective of rewarding Mr. Hashem for building an integrated product group that encompasses all of NOW’s existing software assets; whereas the former earn-out provisions were based on performance of the Smartlytics business unit only. Mr. Hashem was promoted to the EVP Product & Technology role in early 2024.

TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce that it has sourced historic exploration data relating to the Lutila Gold Project (the “Property”) located in Slovakia. This information has now been validated and incorporated into the Company’s database. The Lutila exploration licence covers an area of 32.2km² and is prospective for quartz-adularia epithermal gold mineralisation.

WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024.

Revenue up 20% year-over-year on strong demand

BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.

• Consolidated revenues were $704 million, up 8.0%, and up 6.9% on an organic constant currency (OCC) basis for the first quarter of 2024.

CEO Dave Anthony and CFO David Wiens to host live, interactive webinar at 11:00am Pacific Time / 2:00pm Eastern time on Tuesday, May 7. Investors are invited to register at link below.

SPOKANE, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2024. Net income and earnings per diluted share for the first quarter of 2024 compared to the first quarter of 2023 are presented in the table below (dollars in thousands, except per-share data):

SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:

Acquisition strengthens presence in the Mid-Atlantic U.S.

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 –

-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 --

-- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK--

First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth

First Quarter Net Sales Increased 2% to $112 million With Vita Coco Coconut Water Growth of 1%